CATXCATXHealthcare · Medical Devices

CATX Stock Forecast: Perspective Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.75
−3.36% on the day

The median 12-month analyst price target for Perspective Therapeutics, Inc. is $9.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$90.6M
Ticker Nerd rank
11/ 100
Median analyst target
$9.50
Analysts covering
16
Revenue$0.0
Operating income−$29.3M
Net income−$26.8M
Free cash flow−$34.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.8%
1M
−67.2%
YTD
−72.6%
1Y
−64.4%
From 52W high
−86.7%
From 52W low
0.0%
$0.75
$5.65
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Perspective Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
11/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
54
Revisions
28
Momentum
26
Accruals
25
Growth
21
Volatility
20
Issuance
19
Value
19

Quality (54): The business earns solid, repeatable profits on what it owns.

Value (19): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CATX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CATX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26CATXHigh $15.00Median $9.50Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
14
Buy
2
Hold
0
Sell
$1.00
Low
$9.50
Median
$15.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Nov 2026Piper SandlerMaintainsOverweight—
10 Nov 2026Truist SecuritiesMaintainsBuy—
10 Nov 2026WedbushMaintainsOutperform—
26 Oct 2026RBC CapitalDowngradeSector Perform—
7 Oct 2026BTIGReiteratesBuy—
18 Sept 2026William BlairInitiatesOutperform—
15 Sept 2026WedbushReiteratesOutperform—
19 Aug 2026BMO CapitalInitiatesOutperform—
14 Aug 2026B of A SecuritiesMaintainsNeutral—
11 Aug 2026Piper SandlerMaintainsOverweight—
5 May 2026BTIGReiteratesBuy—
5 May 2026WedbushReiteratesOutperform—
20 Apr 2026WedbushReiteratesOutperform—
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
18 Mar 2026B. Riley SecuritiesMaintainsBuy—
18 Mar 2026UBSMaintainsBuy—
18 Mar 2026WedbushReiteratesOutperform—
17 Mar 2026BTIGReiteratesBuy—
17 Mar 2026RBC CapitalMaintainsOutperform—
19 Feb 2026Piper SandlerInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CATX.

Market Radar

This page is one stock. Monday covers all of them.

CATX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CATX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Perspective Therapeutics, Inc. returned −64.4% against +6.9% for the S&P 500, dividends included.

CATX vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300Jan 26Apr 26Jul 26Oct 26CATXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CATX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
413.8×

Cheaper than 1% of US stocks

Price / book
0.3×

Cheaper than 92% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−90.4%

Higher than 2% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−45.9%

Higher than 23% of US stocks

Return on assets
−24.9%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Perspective Therapeutics, Inc. has a market value of $90.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$116.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$121.2M.

  • Shares outstanding: 114.1M.

  • Perspective Therapeutics, Inc. employs 163 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

CATX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CATXPerspective Therapeutics, Inc.$90.6M11
QTRXQuanterix Corp.$92.3M53
STIMNeuronetics, Inc.$95.2M64
OWLTOwlet, Inc.$85.0M27
APYXApyx Medical Corp.$101.1M76
LUCDLucid Diagnostics, Inc.$75.7M36
LUNGPulmonx Corp.$111.9M87

Take a look at CATX’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Perspective Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CATX

What is the CATX stock price forecast for 2026-2027?

The median 12-month analyst price target for Perspective Therapeutics, Inc. is $9.5, with estimates ranging from $1 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CATX stock a buy right now?

Of the 16 analysts covering Perspective Therapeutics, Inc., 14 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Perspective Therapeutics, Inc. 11 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CATX?

As at 21 Nov 2026, Perspective Therapeutics, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (54 of 100).

Will CATX stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts is $9.5, and Ticker Nerd's factor model ranks Perspective Therapeutics, Inc. 11 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CATX stock forecast for 2030?

No analyst covering Perspective Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CATX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $15 over the next 12 months.

How has CATX stock performed over the past year?

Perspective Therapeutics, Inc. returned -64.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Perspective Therapeutics, Inc. do?

Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer. The company’s current portfolio centers on treatments and companion imaging agents designed to deliver radiation directly to tumors while helping physicians visualize disease and tailor care.

Company

About Perspective Therapeutics, Inc.

Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer. The company’s current portfolio centers on treatments and companion imaging agents designed to deliver radiation directly to tumors while helping physicians visualize disease and tailor care. Its programs are built around proprietary lead-212-based technology and a theranostic approach that combines diagnosis and treatment in a single oncology platform. Perspective Therapeutics is active in several cancer areas, including neuroendocrine tumors, metastatic melanoma, and other solid tumors, through its clinical-stage development efforts. The company also works on complementary tools and manufacturing capabilities that support its radiopharmaceutical pipeline and clinical operations. Based in Seattle, Perspective Therapeutics plays a specialized role in the broader oncology market by advancing targeted nuclear medicine approaches for cancer care.

CEO Mr. Johan M. Spoor · 163 employees · United States · https://www.perspectivetherapeutics.com